Department of Surgery, Transplantation Surgery, University of Nebraska Medical Center, Omaha, Nebraska, USA.
Department of Pediatrics, Division of Blood and Marrow Transplantation, University of Nebraska Medical Center, Omaha, Nebraska, USA.
Pediatr Transplant. 2022 Aug;26(5):e14287. doi: 10.1111/petr.14287. Epub 2022 Apr 10.
Pediatric myelodysplastic syndrome is a rare but life-threatening condition requiring prompt recognition and management.
We herein present the only reported case of a pediatric multi-organ transplant recipient developing myelodysplastic syndrome.
The patient was a 14-year-old girl on chronic calcineurin inhibitor therapy who presented with peri-rectal pain approximately 13 years after liver, small bowel, and pancreas transplant. The initial workup revealed pancytopenia and parvovirus B19 viremia. Her definitive diagnosis was complicated by a lack of adequate bone marrow biopsy specimens and expert consultation that resulted in treatment for hemophagocytic lymphohistiocytosis. She was later diagnosed with high-grade myelodysplastic syndrome. Although curative treatment with chemotherapy and hematopoietic stem cell transplantation was strongly considered, it was not performed due to the child's rapid clinical progression, ventilator status, and active infections. The patient died approximately 6 months following symptom onset.
This case emphasizes the importance of early recognition of myelodysplastic syndrome in multi-organ transplant recipients on chronic immunosuppression. Pancytopenia is a common presentation in the post-transplant period that requires thorough investigation. Multiple confounding considerations such as infection, immunosuppression, and systemic inflammation can delay the diagnosis of underlying hematological malignancies. Transplant care providers should be aware of myelodysplastic syndrome and advocate for a comprehensive evaluation, given early recognition and intervention can significantly improve outcomes.
儿科骨髓增生异常综合征是一种罕见但危及生命的疾病,需要及时识别和治疗。
我们在此报告了一例儿科多器官移植受者发生骨髓增生异常综合征的病例。
该患者为一名 14 岁女孩,长期接受钙调神经磷酸酶抑制剂治疗,在肝、小肠和胰腺移植后约 13 年出现肛周疼痛。最初的检查发现全血细胞减少和微小病毒 B19 血症。由于缺乏足够的骨髓活检标本和专家咨询,导致治疗方案被误诊为噬血细胞性淋巴组织细胞增生症,最终确诊为高级别骨髓增生异常综合征。尽管强烈考虑采用化疗和造血干细胞移植进行根治性治疗,但由于患儿病情迅速恶化、需要呼吸机支持以及存在活动性感染,未进行上述治疗。患者大约在症状出现后 6 个月死亡。
本病例强调了慢性免疫抑制的多器官移植受者中早期识别骨髓增生异常综合征的重要性。全血细胞减少是移植后常见的表现,需要进行彻底的检查。感染、免疫抑制和全身炎症等多种混杂因素会延迟潜在血液系统恶性肿瘤的诊断。移植治疗医生应了解骨髓增生异常综合征,并提倡进行全面评估,因为早期识别和干预可以显著改善预后。